TY - JOUR
T1 - Why will it never be known if convalescent plasma is effective for COVID-19
AU - Rojas, Manuel
AU - Anaya, Juan Manuel
N1 - Funding Information:
This work was supported by Universidad del Rosario (ABN-011), Bogota, Colombia.
Publisher Copyright:
© 2020 The Authors
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.
AB - High expectations have been set around convalescent plasma (CP) for the treatment of COVID-19. However, none of the randomized controlled trials (RCTs) conducted so far have reached their primary endpoints. Herein we report that RCTs of CP disclose a high methodological variability in inclusion criteria, outcomes, appropriate selection of donors, dosage, concentration of neutralizing antibodies and times of transfusion. Therefore, at this time there is insufficient evidence to recommend for or against the use of CP as a treatment for COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85096882919&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096882919&partnerID=8YFLogxK
U2 - 10.1016/j.jtauto.2020.100069
DO - 10.1016/j.jtauto.2020.100069
M3 - Review article
C2 - 33169114
AN - SCOPUS:85096882919
SN - 2589-9090
VL - 3
JO - Journal of Translational Autoimmunity
JF - Journal of Translational Autoimmunity
M1 - 100069
ER -
